Biotech Values

[mcbio]

The data reported below speak for themselves and make it clear, IMO, that TMC435 is the best HCV protease inhibitor on the market or in late-stage development.

Pretty hard to disagree with you on this. I only wish TMC435 were still unpartnered, but presumably Medivir would be at a higher valuation anyways if TMC435 were still unpartnered (on the expectation of a lucrative deal); I think JNJ ought to go ahead and consider acquiring Medivir outright, at this valuation.